[go: up one dir, main page]

PA8613001A1 - Derivados de triazol sustituidos como antagonistas de oxitocina - Google Patents

Derivados de triazol sustituidos como antagonistas de oxitocina

Info

Publication number
PA8613001A1
PA8613001A1 PA20048613001A PA8613001A PA8613001A1 PA 8613001 A1 PA8613001 A1 PA 8613001A1 PA 20048613001 A PA20048613001 A PA 20048613001A PA 8613001 A PA8613001 A PA 8613001A PA 8613001 A1 PA8613001 A1 PA 8613001A1
Authority
PA
Panama
Prior art keywords
oxitocine
antagonists
derivatives replaced
triazol derivatives
inhibitors
Prior art date
Application number
PA20048613001A
Other languages
English (en)
Inventor
David Ellis
Alan Daniel Brown
Christopher Ronald Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322159A external-priority patent/GB0322159D0/en
Priority claimed from GB0403150A external-priority patent/GB0403150D0/en
Priority claimed from GB0415110A external-priority patent/GB0415110D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8613001A1 publication Critical patent/PA8613001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA CLASE DE 1,2,3-TRIAZOLES SUSTITUIDOS DE FORMULA (1) CON ACTIVIDAD COMO ANTAGONISTAS OXITOCINA, A SUS USOS , A PROCESOS PARA SU PREPARACION Y A COMPOSICIONES QUE CONTIENEN DICHO INHIBIDORES. ESTOS INHIBIDORES TIENEN UTILIDAD EN UNA DIVERSIDAD DE AREAS TERAPEUTICAS INCLUYENDO LA DISFUCION SEXUAL,PARTICULARMENTE LA EYACULACION PRECOZ (P.E.).
PA20048613001A 2003-09-22 2004-09-21 Derivados de triazol sustituidos como antagonistas de oxitocina PA8613001A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322159A GB0322159D0 (en) 2003-09-22 2003-09-22 New substituted triazoles for use as novel pharmaceuticals
GB0403150A GB0403150D0 (en) 2004-02-12 2004-02-12 Novel pharmaceuticals
GB0415110A GB0415110D0 (en) 2004-07-05 2004-07-05 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
PA8613001A1 true PA8613001A1 (es) 2005-08-04

Family

ID=34381637

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048613001A PA8613001A1 (es) 2003-09-22 2004-09-21 Derivados de triazol sustituidos como antagonistas de oxitocina

Country Status (12)

Country Link
EP (1) EP1673355A1 (es)
JP (1) JP2007505888A (es)
AR (1) AR045791A1 (es)
BR (1) BRPI0414663A (es)
CA (1) CA2539297C (es)
MX (1) MXPA06003158A (es)
NL (1) NL1027084C2 (es)
PA (1) PA8613001A1 (es)
PE (1) PE20050950A1 (es)
TW (1) TW200526606A (es)
UY (1) UY28524A1 (es)
WO (1) WO2005028452A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1817295B1 (en) * 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
EP1863795B1 (en) * 2005-03-21 2008-10-29 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US20080214622A1 (en) * 2005-03-21 2008-09-04 Alan Daniel Brown Substituted Triazole Derivatives As Oxytocin Antagonists
KR101346902B1 (ko) 2005-07-09 2014-01-02 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
WO2007017752A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
DE102006059710A1 (de) * 2006-12-18 2008-06-19 Freie Universität Berlin Substituierte 4-Hydroxypyridine
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
EP3501533B1 (en) 2014-12-22 2025-07-09 Ferring B.V. Obe001 for use in the treatment in implantation and pregnancy in women undergoing assisted reproductive technologies
KR20190094187A (ko) * 2016-12-21 2019-08-12 지앙수 헨그루이 메디슨 컴퍼니 리미티드 축합 고리기 아자시클로부틸 트리아졸 유도체, 이의 제조 방법 및 의약에서의 이의 용도
MX2019007360A (es) 2016-12-28 2019-08-16 Jiangsu Hengrui Medicine Co Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.
TW202016091A (zh) * 2018-06-20 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｏｔｒ抑制劑的可藥用鹽、晶型及製備方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法
JP2022042278A (ja) * 2020-09-02 2022-03-14 国立大学法人浜松医科大学 化合物又はその塩及び中枢オキシトシン受容体イメージング剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
WO2001058880A1 (en) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Novel triazole derivatives
PL359340A1 (en) * 2000-05-19 2004-08-23 Triazole derivatives
ATE297913T1 (de) * 2001-07-05 2005-07-15 Pfizer Prod Inc Sulfonyl-heteroaryl-triazole als entzündungshemmende und analgetische mittel
IL162615A0 (en) * 2001-12-20 2005-11-20 Applied Research Systems Triazole derivatives, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP2007505888A (ja) 2007-03-15
WO2005028452A9 (en) 2005-07-21
BRPI0414663A (pt) 2006-11-21
NL1027084A1 (nl) 2005-03-24
PE20050950A1 (es) 2005-11-11
WO2005028452A1 (en) 2005-03-31
TW200526606A (en) 2005-08-16
AR045791A1 (es) 2005-11-16
EP1673355A1 (en) 2006-06-28
MXPA06003158A (es) 2006-06-05
NL1027084C2 (nl) 2006-01-24
CA2539297C (en) 2010-07-20
CA2539297A1 (en) 2005-03-31
UY28524A1 (es) 2005-04-29

Similar Documents

Publication Publication Date Title
PA8613001A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
CR9219A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
UY27807A1 (es) Nuevos derivados de piridazin-3(2h)-ona
UY30942A1 (es) Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida
CL2004002050A1 (es) Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
PA8557101A1 (es) Benzimidazoles
ES2183937T3 (es) Inhibidores de la adhesion celular.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
PA8609701A1 (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
SV2003000925A (es) Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
CR7899A (es) Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
BRPI0514736A (pt) inibidores do receptor sigma
PA8577201A1 (es) 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b
MXPA05002652A (es) Composicion oralmente administrable para mejorar la calidad de la piel.
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.